🇺🇸 FDA
Patent

US 8012965

Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors

granted A61PA61P13/12A61P17/06

Quick answer

US patent 8012965 (Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Sep 06 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61P, A61P13/12, A61P17/06, A61P19/00, A61P19/02